Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

HP Ingredients Executive to Speak at Industry Conference

<p>Executive Vice President of HP Ingredients will speak at the 2nd Annual Dietary Supplements: Regulatory Strategy Conference, held November 13 and 14 in Arlington, VA.</p>

Press Release

“Dietary Supplement Manufacturer Oversight of Distributor and Contract Manufacturer GMPs” is the subject that Hame Persaud, Executive Vice President of HP Ingredients will discuss at the 2nd Annual Dietary Supplements:  Regulatory Strategy Conference, held November 13 and 14 at the Sheraton Pentagon City Hotel, Arlington, VA. Persaud’s segment is scheduled for 10:00 am, Tuesday, November 14.

Achieving safety (and thus quality) of the nutraceutical product while keeping economies of production and oversight at attractive levels is an achievable goal, according to Persaud.

“To leverage savings in costs, many dietary supplement manufacturers and brands work with distributors and contract manufacturers to produce safe, trustworthy products while reducing overall product costs,” he says.  “However, these relationships often create an additional layer of risk and necessity to monitor to ensure products remain unadulterated.”

Therefore, he explains, creating and following a risk-adverse protocol to manufacturing necessitates the ability to recognize areas of required oversight of contract manufacturers in maintaining alignment with GMP standards and distributor oversight of GMP activities.

Persaud will discuss four key steps in creating the successful risk-adverse protocol:

  • Defining responsibilities of manufacturers & distributors
  • Ensuring product specifications are being consistently met
  • Batch record management at contract facilities
  • Adulteration concerns surrounding GMP compliance

“As claims of adulteration and FDA inspection activity continues to increase, appropriate oversight and monitoring to ensure GMP alignment is of critical importance,” he says.

For more information about the conference, please visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.